Treatment Utility of Postpartum Antibiotics in Chorioamnionitis (TUPAC)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To determine if prophylactic postpartum antibiotics are required post-cesarean delivery for pregnancies with treated chorioamnionitis.
| Condition | Intervention | Phase |
|---|---|---|
|
The Primary Outcome of This Study Will be the Rate of Endometritis in the Study Population. |
Drug: Postpartum Antibiotics Drug: No postpartum antibiotics |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Subject) Primary Purpose: Treatment |
| Official Title: | Treatment Utility of Postpartum Antibiotics in Chorioamnionitis |
- Endometritis [ Time Frame: 7 days post-partum ] [ Designated as safety issue: No ]Endometritis is defined as maternal temp > 38.0C on two occasions over a 4 hour period or any temp > 39.0C after delivery > 12 hours after delivery. Endometritis will be managed per currently accepted endometritis protocol - (Amp 2 gQ6, Gentamicin 5 mg/kg q24, Clindamycin 900 mg q8).
- Infection-related complications [ Time Frame: 7 days post-partum ] [ Designated as safety issue: No ]To include wound infections, pelvic abscesses, etc.
- Duration of hospital stay [ Time Frame: 7 days post-partum ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 238 |
| Study Start Date: | September 2010 |
| Estimated Study Completion Date: | July 2013 |
| Estimated Primary Completion Date: | July 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Postpartum Antibiotics
Patients will receive one additional dose of postpartum antibiotics (Clinda, Gentamicin)
|
Drug: Postpartum Antibiotics
Patients randomized into this arm will receive one additional dose of gentamicin (1.5 mg/kg) and clindamycin (900mg) in the postpartum setting.
|
|
Placebo Comparator: No postpartum antibiotics
No further postpartum antibiotics
|
Drug: No postpartum antibiotics
Patients randomized into this arm will not receive any postpartum antibiotics after delivery. They will be managed identically to the other arm in terms of chorioamnionitis (fever pre-delivery). The groups will be managed identically if endometritis (post-partum fever) develops.
|
Detailed Description:
Bacterial infection of the amniotic cavity, termed "chorioamnionitis", is a major cause of perinatal mortality and maternal morbidity. Early administration of broad-spectrum antibiotic therapy in the laboring patient with chorioamnionitis has both neonatal and maternal benefits. Less known is the ideal postpartum antibiotic regimen - or if postpartum antibiotics are even required at all - needed to decrease febrile morbidity. Current practice has seen a wide range of practice styles ranging from no treatment to antibiotic prophylaxis for up to 48 hours after delivery.
If antibiotics are prescribed, there is good evidence to support one additional dose of antibiotics as compared to 24 hour dosing to decrease the rate of endometritis. Less clear is whether antibiotics are required at all for the properly treated patient with chorioamnionitis who requires a cesarean delivery. One study comparing continued antibiotics versus no-treatment failed to show a difference in the rate of postpartum endometritis. The conclusion from this study was that continuation of preoperative clindamycin and gentamicin in the postoperative period did not reduce the risk of endometritis compared to a single preoperative dose however this study was terminated early due to failure to recruit their stated sample size.
Puerperal endometritis rates vary by mode of delivery but it is known that the rate is lower in vaginal deliveries as compared to cesarean delivery. The patient with chorioamnionitis that requires a cesarean delivery makes an excellent study target. Given the lack of studied protocols, there currently are many acceptable methods for treating the patient with chorioamnionitis. Our proposed study plans to evaluate the two most common methods of treatment to determine the most effective regimen. If post-delivery antibiotics do not show a benefit to these highest risk subjects, it is likely inferred that patients that undergo a vaginal delivery will not require antibiotics as well.
Specific Aims There is conflicting data regarding the necessity of post-delivery antibiotics for patients with chorioamnionitis who undergo cesarean delivery. The primary objective of this study is to determine if postpartum antibiotics are necessary for antepartum treated cases of chorioamnionitis in patients undergoing a cesarean section.
Eligibility| Ages Eligible for Study: | 14 Years to 50 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Clinical diagnosis of chorioamnionitis
- Undergoing cesarean section for delivery
Exclusion Criteria:
- Multiple gestations,
- Allergy to beta-lactam antibiotics
- Patients with estimated creatinine clearance (ClCr) less than 70 mL/min
- Maternal fever explained by etiology other than chorioamnionitis
- Inability to comply with the study protocol.
Contacts and Locations| United States, Missouri | |
| Barnes-Jewish Hospital | Recruiting |
| St. Louis, Missouri, United States, 63110 | |
| Contact: Anthony Shanks, MD 314-362-7315 shanksa@wudosis.wustl.edu | |
| Principal Investigator: Anthony Shanks, MD | |
| St. Louis University | Not yet recruiting |
| St. Louis, Missouri, United States, 63110 | |
| Contact: Anthony Shanks, MD 314-362-7315 shanksa@wudosis.wustl.edu | |
| Principal Investigator: Anthony Shanks, MD | |
More Information
Publications:
| Responsible Party: | Anthony Shanks, MD, Assistant Professor, Washington University School of Medicine |
| ClinicalTrials.gov Identifier: | NCT01585129 History of Changes |
| Other Study ID Numbers: | 09-0704 |
| Study First Received: | April 23, 2012 |
| Last Updated: | April 24, 2012 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Fetal Diseases Chorioamnionitis Endometritis Pregnancy Complications Fetal Membranes, Premature Rupture Obstetric Labor Complications Placenta Diseases Pelvic Inflammatory Disease |
Adnexal Diseases Genital Diseases, Female Uterine Diseases Anti-Bacterial Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 19, 2013